收入和财务状况 - Agenus Inc.在2023年第四季度和全年度报告中，收入为1.56亿美元，净亏损为2.57亿美元[18] - Agenus公司在2023年第四季度和全年度报告中，现金余额为7,610万美元[19] - Agenus公司从BMS获得了2500万美元的里程碑付款[17] BOT/BAL在不同癌症类型中的表现 - BOT/BAL在难治性结直肠癌患者中表现出24%的持久ORR[2] - BOT/BAL在2L转移性胰腺癌患者中显示出显著的肿瘤标志物减少[9] - BOT/BAL在2L+黑色素瘤患者中展示了30%的ORR和60%的疾病控制率[11] - BOT/BAL在PD(L)-1难治性NSCLC患者中表现出56%的ORR和89%的疾病控制率[13] - BOT/BAL在晚期肉瘤患者中显示出20%的ORR和19.4个月的中位反应持续时间[14] - BOT/BAL在难治性卵巢癌患者中观察到33%的总体反应率[16] 合作与商业化 - Agenus公司正在积极与多家潜在生物制药合作伙伴进行合作开发和共同商业化BOT/BAL的讨论[17]

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively. The Compen ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, plea ...

Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (AGEN -29.54%) experienced this vividly on Thursday when their company announced its intention to start going down that road. The stock's price fell sharply, by almost 30%, contrasting with the 0.6% gain of the benchmark S&P 500 index.Twenty shares will become oneIn a regulatory filing and a letter to its shareholders, both publish ...

Stay on the Internet long enough – and it won’t take too long, believe me – and you’ll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don’t always get the love from retail investors. Plus, they tend to be conservative for good reason. You don’t want to destroy your reputation by endorsing junk securities.That said, we’re all human. And humans love every now and then to speculate – even th ...

生物技术行业表现 - SPDR S&P生物技术ETF在过去三个月中上涨了31%[1] - Eli Lilly and Company (LLY)是2023年表现最好的生物技术股之一，股价飙升超过70%，主要原因是公司新的肥胖药物Zepbound在2023年11月获得批准[4] - Amylyx (AMLX)是一家在2022年获得FDA批准的公司，其主打治疗ALS的药物Relyvrio已经带来了三个盈利季度，预计未来12个月盈利将增长约79%[8]

wildpixel Agenus Inc. (NASDAQ:AGEN), a pioneer in immunological cancer treatments, has recently unveiled impressive results from the NEST-1 study. This investigator-sponsored trial ("IST") focused on evaluating the combination of botensilimab and balstilimab ((BOT/BAL)) in the neoadjuvant setting for colorectal cancer (CRC). The data from the NEST-1 study present BOT/BAL as a potential game-changer in CRC treatment. The combination's ability to induce significant tumor regression and eliminate ctDNA ope ...

Agenus Inc.新药研究 - Agenus Inc.宣布NEST-1研究结果，评估BOT/BAL在结直肠癌新辅助治疗中的潜力[1] - BOT/BAL治疗方案在MSS和MSI-H CRC患者中显示出显著的肿瘤缩小和ctDNA消除效果[2] - Botensilimab是一种多功能抗CTLA-4免疫激活剂，可增强抗肿瘤免疫反应[3]

公司产品管线 - 公司的产品管线围绕着Belrestotug [EOS-448]和Inupadenant [EOS-850]进行开发[2] 公司财务状况 - 公司的现金及现金等价物截至2023年9月30日为6.449亿美元，足以支持其运营至2026年[8]